Rubra Medicaments reports standalone net profit of Rs 0.01 crore in the September 2022 quarter

Rubra Medicaments reports standalone net profit of Rs 0.01 crore in the September 2021 quarter

Hasn't fared well - amongst the low performers

Seems to be overvalued vs the market average

Lagging behind the market in financials growth

Average profitability - not good, not bad

Good time to consider, stock is not in the overbought zone

The stock has a moderate number of red flags

Checkpoint Trends Limited operates in trading and consultancy services, focusing on a single business segment of trading.